Blog & Commentary

The use of asbestos in building materials has decreased in the United States during the past several decades due to its worldwide recognition as a deadly carcinogen. At the same time, however,… Read More

In 2011, Mike Mattmuller was only 29-years-old when an x-ray revealed he had mesothelioma – an often fatal form of cancer caused by asbestos exposure that typically afflicts people twice his age.… Read More

In the first talc trial to be held before a state jury in California, multinational pharma giant Johnson & Johnson lost $417 million in compensatory and punitive damages to a Los Angeles… Read More

Nearly 3,000 people are diagnosed with mesothelioma every year, all of whom face uncertain futures that may include chemotherapy, radiation and mounting hospital bills. While many tend to focus on treating the… Read More

Today begins our series of Miles for Meso spotlights. Every week between now and race day on Sept. 30, the Simmons Hanly Conroy blog will feature a survivor, warrior, volunteer or organization… Read More

At a vital turning point in opioid litigation, law firms like Simmons Hanly Conroy are now casting their net beyond chronic pain patients, whose lawsuits against opioid makers have generated millions in… Read More

Daiichi Sankyo, Inc., a Tokyo-based drug maker worth an estimated $12.4 billion, agreed to settle nearly 2,300 patient lawsuits against its blood pressure medication Benicar® (olmesartan medoxomil) and its sister medications Benicar… Read More

The upcoming release of Paul Shanley, defrocked priest and convicted child-rapist, is an appalling reminder of the injustice suffered by survivors of clergy abuse. After spending 12 years in prison, Shanley will… Read More

“Don’t smoke – you could get lung cancer.” You may have heard these words at some point in your life. It’s often one of the leading arguments to convince people to avoid… Read More

On July 8 – in a first of its kind decision – the Food and Drug Administration (FDA) requested a pharmaceutical company to pull off the market one of its opioid products… Read More